Genotypic analysis of HIV resistance;L'analyse génotypique de la résistance du VIH

Medecine Therapeutique

Volumn 8, Issue SPEC. ISS. 1, 2002, Pages 36-41

  Clevenbergh, Philippe ^a   Blaise, Pierre ^a   Okome Nkoumou, Madeleine ^a   Dellamonica, Pierre ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PROTOCOL; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS; LABORATORY DIAGNOSIS; LYMPHOCYTE COUNT; NONHUMAN; REVIEW; VIRUS RESISTANCE;

EID: 0036161467     PISSN: 12646520     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Hidden dangers of incompletely suppressive antiretroviral therapy
2. Les multiples aspects de la résistance du VIH aux antirétroviraux
3. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs)
4. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase
5. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates
6. The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance
7. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
8. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
9. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
10. Phenotypic resistance testing significantly improves response to therapy: A randomized trial (VIRA 3001)
11. Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: A randomized trial (NARVAL, ANRS 088)
12. The potential role of resistance decision support software with or without expert advice in a trial of HIV genotyping versus standard of care - The Havanna trial
13. Impact of phenotypic antiretroviral drug resistance testing on the response to salvage antiretroviral therapy (ART) in heavily experienced patients
14. A prospective, randomized study on the usefulness of genotypic resistance testing and the assessment of patient-reported adherence in unselected patients failing potent HIV therapy (ARGENTA): Final 6-month results
15. Drug resistance and the management of treatment failure
16. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
17. Zidovudine associated resistance mutations can be selected in patients receiving long-term exposure to stavudine
18. Presence of thymidine-associated mutations and response to d4T, abacavir and ddl in the control arm of the NARVAL ANRS 088 trial
19. Prise en charge thérapeutique des personnes infectées par le Vih. Recommandations du groupe d'experts. Mise àjour 2000 du rapport 1999 sous la direction du professeur Delfraissy
20. Réunion de travail GlaxoWellcome sur les résistances
21. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase
22. Second worldwide evaluation of HIV-1 drug resistance genotyping quality, using the ENVA-2 panel
23. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an international AlDS society-USA panel